Clinical research partner dMed has completed a series B round that included returning investor Lilly Asia Ventures as it seeks to expand internationally.
China-based clinical research provider dMed Biopharmaceutical recently closed a $50m series B round featuring Lilly Asia Ventures, an investment vehicle overseen by pharmaceutical firm Eli Lilly, it announced on Wednesday.
Healthcare investment firm Vivo Capital led the round, which included Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, and fellow VC firm Qiming Venture Partners.
Founded in 2016, dMed is a contract research organisation (CRO) that performs a range of services covering areas like pharmacology, clinical work,…
